(Q36107130)

12 August 2017

Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide (English)

1 reference

12 August 2017

1 reference

6

Gunnar Mellgren

1 reference

12 August 2017

Aliana Guerrieri Gonzaga

0 references

author name string

Jennifer Gjerde

1

1 reference

12 August 2017

Sara Gandini

2

1 reference

12 August 2017

Aliana Guerrieri-Gonzaga

3

1 reference

12 August 2017

Line L Haugan Moi

4

1 reference

12 August 2017

Valentina Aristarco

5

1 reference

12 August 2017

Andrea Decensi

7

1 reference

12 August 2017

Ernst A Lien

8

1 reference

12 August 2017

language of work or name

English

0 references

publication date

5 May 2012

1 reference

Breast Cancer Research and Treatment

12 August 2017

1 reference

12 August 2017

134

1 reference

12 August 2017

2

1 reference

12 August 2017

693-700

1 reference

SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3401496

Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3401496

Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3401496

Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3401496

Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3401496

Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3401496

Genotype-guided tamoxifen therapy: time to pause for reflection?

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3401496

Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3401496

Controversies in the management of patients with breast cancer: adjuvant endocrine therapy in premenopausal women

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3401496

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3401496

Adherence to endocrine therapy for breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3401496

The role of flavin-containing monooxygenase (FMO) in the metabolism of tamoxifen and other tertiary amines

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3401496

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3401496

Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3401496

Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3401496

Association of tamoxifen (TAM) and TAM metabolite concentrations with self-reported side effects of TAM in women with breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3401496

Oxidative metabolism of tamoxifen to Z-4-hydroxy-tamoxifen by cytochrome P450 isoforms: an appraisal of in vitro studies

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3401496

Aging may be associated with concentrations of tamoxifen and its metabolites in breast cancer patients

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3401496

Overview of the main outcomes in breast-cancer prevention trials

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3401496

Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3401496

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3401496

Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3401496

Genetic polymorphisms of CYP2D6*10 and CYP2C19*2, *3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3401496

Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3401496

Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen.

2 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2074-9

Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2074-9

Oxidation of tamoxifen by human flavin-containing monooxygenase (FMO) 1 and FMO3 to tamoxifen-N-oxide and its novel reduction back to tamoxifen by human cytochromes P450 and hemoglobin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2074-9

A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2074-9

Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2074-9

Identification and quantification of tamoxifen and four metabolites in serum by liquid chromatography-tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2074-9

Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2074-9

Tamoxifen in liver disease: potential exacerbation of hepatic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2074-9

Biomonitoring of urinary tamoxifen and its metabolites from breast cancer patients using nonaqueous capillary electrophoresis with electrospray mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2074-9

Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2074-9

Noncompliance with adjuvant radiation, chemotherapy, or hormonal therapy in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2074-9

Undertreatment strongly decreases prognosis of breast cancer in elderly women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2074-9

A menopause-specific quality of life questionnaire: development and psychometric properties.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3401496

Development and validation of a quantitative assay for the determination of tamoxifen and its five main phase I metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry

23 September 2018

1 reference

12 December 2020

High-affinity binding to the estrogen receptor of [3H]4-hydroxytamoxifen, an active antiestrogen metabolite

1 reference

12 December 2020

Metabolism of tamoxifen by isolated rat hepatocytes: anti-estrogenic activity of tamoxifen N-oxide

1 reference

12 December 2020

Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile

1 reference

12 December 2020

Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation

1 reference

12 December 2020

Pharmacokinetics of tamoxifen in premenopausal and postmenopausal women with breast cancer

1 reference

12 December 2020

1 reference

12 December 2020

Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes

1 reference

12 December 2020

10.1007/S10549-012-2074-9

Identifiers

DOI

1 reference

12 August 2017

1 reference

12 August 2017

PubMed publication ID

22562123

1 reference